⏳ Fetching live dividend data...
Home › Calculator › ICAD Dividend Calculator 2026
iCAD, Inc. · NASDAQ
Price: $3.87 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
ICAD is not a dividend-focused stock
ICAD pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
iCAD, Inc. (ICAD) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
iCAD, Inc. specializes in delivering advanced solutions for cancer management, encompassing sophisticated image analysis tools, streamlined workflow optimization, and targeted radiation therapy. While primarily operating in the United States, the company also maintains a significant international presence. Its operations are organized into two principal divisions: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, iCAD provides a range of innovative technologies. This includes the PowerLook platform, which serves as a central host for artificial intelligence algorithms and facilitates seamless communication between imaging acquisition devices, storage systems, and review platforms. Key diagnostic offerings feature SecondLook, a machine learning-driven algorithm designed to examine 2D full-field digital mammography images for identifying and marking suspicious masses and calcifications. Additionally, the company offers automated solutions for consistent and standardized assessment of breast density. Its portfolio further extends to ProFound AI, a deep-learning algorithm adept at detecting malignant soft-tissue densities and calcifications within digital breast tomosynthesis, and ProFound AI Risk, a tool that provides breast cancer risk estimation derived from screening mammograms. Magnetic resonance imaging (MRI) applications are also available for detecting breast and prostate cancer, along with VeraLook, a solution supporting the identification of colonic polyps in conjunction with CT Colonography. The Cancer Therapy division features the Xoft Axxent electronic brachytherapy systems. These systems are employed in the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. Their clientele is diverse, spanning university research centers, community hospitals, specialized cancer care clinics, veterinary facilities, and dermatology practices. iCAD distributes its products through multiple channels, utilizing its own direct sales organizations, as well as collaborating with original equipment manufacturer (OEM) partners, various distributors, technology platform partners, and resellers. The company also has a global footprint, exporting its advanced technologies to regions including Europe, Taiwan, Canada, China, and other international markets. Originally established in 1984 under the name Howtek, Inc., the company was rebranded as iCAD, Inc. in June 2002. Its corporate headquarters are located in Nashua, New Hampshire.
No. iCAD, Inc. (ICAD) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. ICAD has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ICAD position with:
Real after-tax yield depends on where you live and how you hold ICAD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ICAD pays quarterly — 4 times per year. Ex-div: —.
How ICAD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ICAD sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-07-17 | 40,000 | $1.36 | $54.4K | ||
| D-Return | 2025-07-17 | 6,641 | $3.69 | $24.5K | ||
| D-Return | 2025-07-17 | 5,415 | $1.52 | $8.2K | ||
| D-Return | 2025-07-17 | 30,000 | $2.06 | $61.8K | ||
| D-Return | 2025-07-17 | 25,000 | $4.37 | $109.3K | ||
| D-Return | 2025-07-17 | 14,183 | $12.84 | $182.1K | ||
| D-Return | 2025-07-17 | 19,000 | $18.00 | $342.0K | ||
| D-Return | 2025-07-17 | 25,000 | $4.25 | $106.3K | ||
| D-Return | 2025-07-17 | 50,000 | $1.85 | $92.5K | ||
| D-Return | 2025-07-17 | 188,725 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Compare ICAD with peers: ICAD vs ASXC · ICAD vs AUGX · ICAD vs CYT
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ICAD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
iCAD, Inc. (ICAD) is currently trading at $3.87, trading near its 52-week high. It does not currently pay a regular dividend.
iCAD, Inc. (ICAD) is a healthcare stock trading at $3.87. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever